Understanding the role of glucose-dependent insulinotropic polypeptide in managing diabetes and obesity https://lnkd.in/eb3HQXNY https://lnkd.in/eiPY3PUs
Altamiro Bottino’s Post
More Relevant Posts
-
𝗛𝗲𝗮𝗹𝘁𝗵 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗼𝗳 #Mushrooms -Has Anti-Inflammatory Properties -May Help Diabetes Prevention and Treatment -Offers Obesity Support -May Improve Blood Pressure Regulation -May Reduce Depression Risk -Supports Brain Health -Offers Immune Support -May Help Protect Against Cancer Source https://loom.ly/xVYIoMs
-
-
| General and Interventional Cardiologist | MBBS, GDFM, FAMS, MRCP, FRCP, FAsCC, FAPSIC, FSCAI
This is such a big thing. Results of a study just published. Semaglutide is a DIABETES medication in origin. But it's effects are so beneficial that now it can be a WEIGHT management medication in the overweight or obese patient profile with prior cardiovascular disease (even if you don't have diabetes). Proven to reduce the combination end point of cardiovascular deaths, non fatal heart attacks and strokes. #cardiology #weightloss #lifestyle
SELECT trial results presented at #AHA23 show in adults with overweight or obesity who do not have diabetes, semaglutide reduced the risk of major adverse cardiovascular events by 20%.
-
-
The SELECT trial reveal that there are many mechanisms of semaglutide that could attribute for cardiovascular and obesity benefit (cardiovascular benefit, liver disease and inflammatory) independent of weight loss, ➡️hence this make it unwise to stop this medication once achieving target weight loss. ➡️Lack of heterogeneity in achieving primary composite endpoints within different subgroups ➡️achieving clinical significance and numerical reduction in all cause mortality. ➡️economical value is challenging ➡️previous supportive evidence for weight loss independent CVS protective actions of the GLP-1 agonist as in HARMONY Outcomes trial for Albiglutide in type 2 DM there was no body weight difference at 28 weeks, yet 22% reduction in MACE, driven by fewer MI events https://lnkd.in/e98ZtQGF
SELECT trial results presented at #AHA23 show in adults with overweight or obesity who do not have diabetes, semaglutide reduced the risk of major adverse cardiovascular events by 20%.
-
-
Join us for what promises to be a fantastic webinar in our Drug Innovations series: learn about the link between type 2 diabetes and obesity, and much more https://lnkd.in/eV_WWqi4
-
-
We’re excited to showcase our members, including Cynthia Thurlow, ANP, MSN, who are sharing knowledge at our conference. Register and learn about “Inflammation, The Role of Obesity & Poor Metabolic Health” including a review of the Insulin Sensitivity in Obesity Study. https://bit.ly/42eIX28
-
-
Understanding the burden of comorbidities, such as obesity, is important in the holistic management of patients with psoriatic arthritis and psoriasis. Click here to learn more: https://e.lilly/4fsuN3w #PsoriaticArthritis #Psoriasis
-
-
Conquer weight loss and improve overall health with Semaglutide and Tirzepatide. Effective obesity treatment and diabetes management solutions. Read the full blog here!🔽 https://lnkd.in/gNETZUWG #realweightlosspros #semaglutide #tirzepatide #weightlossmedication #obesitytreatment #diabetesmedication #glp1agonist #medicalweightloss #chronicweightmanagement
-
-
With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-
-
With GLP-1 therapies growing in popularity, there’s no better time to get a deeper understanding of how they’ll affect Type 2 diabetes and obesity care. Don’t miss our upcoming webinar to learn about the opportunities and challenges of this new class of drugs for the Type 2 diabesity epidemic: https://lnkd.in/gEHKFxEk #ChronicCare #Diabetes #Webinar
-